Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival

Journal of Cellular Physiology

Volumn 227, Issue 4, 2012, Pages 1326-1334

  Motyl, Katherine J ^a   McCauley, Laurie K ^b,c   McCabe, Laura R ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE REMODELING; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EPIDIDYMIS FAT; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

ACID PHOSPHATASE; ANIMALS; BONE DENSITY; BONE REMODELING; BONE RESORPTION; CELL SURVIVAL; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; HUMANS; ISOENZYMES; MALE; MICE; MICE, INBRED BALB C; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; PARATHYROID HORMONE; RNA, MESSENGER;

MUS;

EID: 80755127897     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22844     Document Type: Article

References (64)

1. Abrahamsen B, Eiken P, Eastell R. 2009. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res 24:1095-1102.
2. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA. 2005. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87:731-741.
3. Auwerx J, Dequeker J, Bouillon R, Geusens P, Nijs J. 1988. Mineral metabolism and bone mass at peripheral and axial skeleton in diabetes mellitus. Diabetes 37:8-12.
4. Barnes GL, Kakar S, Vora S, Morgan EF, Gerstenfeld LC, Einhorn TA. 2008. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am 90:120-127.
5. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. 2003. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259-50272.
6. Botolin S, McCabe LR. 2006a. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 99:411-424.
7. Botolin S, McCabe LR. 2006b. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 209:967-976.
8. Botolin S, McCabe LR. 2007. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 148:198-205.
9. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. 2005. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 146:3622-3631.
10. Bouillon R, Bex M, Van Herck E, Laureys J, Dooms L, Lesaffre E, Ravussin E. 1995. Influence of age, sex, and insulin on osteoblast function: Osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 80:1194-1202.
11. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. 2001. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165.
12. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E. 2001. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107:277-286.
13. Coe LM, Irwin R, Lippner D, McCabe LR. 2010. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol 226:477-483.
14. Danne T, Kordonouri O, Enders I, Weber B. 1997. Factors influencing height and weight development in children with diabetes. Results of the Berlin Retinopathy Study. Diabetes Care 20:281-285.
15. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. 1993. Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709.
16. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G. 2010. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296-308.
17. Follak N, Kloting L, Wolf E, Merk H. 2004. Delayed remodeling in the early period of fracture healing in spontaneously diabetic BB/OK rats depending on the diabetic metabolic state. Histol Histopathol 19:473-486.
18. Fowlkes JL, Bunn RC, Liu L, Wahl EC, Coleman HN, Cockrell GE, Perrien DS, Lumpkin CK, Jr, Thrailkill KM. 2008. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 149:1697-1704.
19. Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY. 2006. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79:262-272.
20. Gandhi A, Beam HA, O'Connor JP, Parsons JR, Lin SS. 2005. The effects of local insulin delivery on diabetic fracture healing. Bone 37:482-490.
21. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. 2007. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 89:349-353.
22. Goodman WG, Hori MT. 1984. Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization. Diabetes 33:825-831.
23. Holl RW, Grabert M, Heinze E, Sorgo W, Debatin KM. 1998. Age at onset and long-term metabolic control affect height in type-1 diabetes mellitus. Eur J Pediatr 157:972-977.
24. Jilka RL. 2007. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446.
25. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. 2009. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 44:275-286.
26. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. 2010. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res 25:2427-2437.
27. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. 2000. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23:295-303.
28. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S. 2007. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92:1172-1175.
29. Krishnan V, Moore TL, Ma YL, Helvering LM, Frolik CA, Valasek KM, Ducy P, Geiser AG. 2003. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol 17:423-435.
30. Kuchler U, Spilka T, Baron K, Tangl S, Watzek G, Gruber R. 2011. Intermittent parathyroid hormone fails to stimulate osseointegration in diabetic rats. Clin Oral Implants Res 22:518-523.
31. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. 2008. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury 39:224-231.
32. Lenart BA, Lorich DG, Lane JM. 2008. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306.
33. Levin ME, Boisseau VC, Avioli LV. 1976. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 294:241-245.
34. Liu CC, Kalu DN. 1990. Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J Bone Miner Res 5:973-982.
35. Liu CC, Kalu DN, Salerno E, Echon R, Hollis BW, Ray M. 1991. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J Bone Miner Res 6:1071-1080.
36. Lozano D, de Castro LF, Dapia S, Andrade-Zapata I, Manzarbeitia F, Alvarez-Arroyo MV, Gomez-Barrena E, Esbrit P. 2009. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 150:2027-2035.
37. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE. 2001. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054.
38. Martin LM, McCabe LR. 2007. Type I diabetic bone phenotype is location but not gender dependent. Histochem Cell Biol 128:125-133.
39. McCabe LR. 2007. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102:1343-1357.
40. Motyl K, McCabe LR. 2009a. Streptozotocin, type I diabetes severity and bone. Biol Proced Online 11:296-315.
41. Motyl KJ, McCabe LR. 2009b. Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice. J Cell Physiol 218:376-384.
42. Motyl KJ, Botolin S, Irwin R, Appledorn DM, Kadakia T, Amalfitano A, Schwartz RC, McCabe LR. 2009. Bone inflammation and altered gene expression with type I diabetes early onset. J Cell Physiol 218:575-583.
43. Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Yamazaki M. 2002. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17:2038-2047.
44. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
45. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. 2008. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346-350.
46. Niziolek PJ, Murthy S, Ellis SN, Sukhija KB, Hornberger TA, Turner CH, Robling AG. 2009. Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment. J Cell Physiol 221:579-585.
47. Ogita M, Rached MT, Dworakowski E, Bilezikian JP, Kousteni S. 2008. Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration. Endocrinology 149:5713-5723.
48. Ontiveros C, McCabe LR. 2003. Simulated microgravity suppresses osteoblast phenotype. Runx2 levels and AP-1 transactivation. J Cell Biochem 88:427-437.
49. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. 2008. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42:806-818.
50. Pierroz DD, Bouxsein ML, Rizzoli R, Ferrari SL. 2006. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 39:260-267.
51. Russell RG. 2006. Bisphosphonates: From bench to bedside. Ann NY Acad Sci 1068:367-401.
52. Russell RG, Rogers MJ. 1999. Bisphosphonates: From the laboratory to the clinic and back again. Bone 25:97-106.
53. Schnoke M, Midura SB, Midura RJ. 2009. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone 45:590-602.
54. Sibonga JD, Iwaniec UT, Shogren KL, Rosen CJ, Turner RT. 2007. Effects of parathyroid hormone (1-34) on tibia in an adult rat model for chronic alcohol abuse. Bone 40:1013-1020.
55. Tanaka S, Sakai A, Tanaka M, Otomo H, Okimoto N, Sakata T, Nakamura T. 2004. Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells. J Bone Miner Res 19:1813-1820.
56. Tashjian AH, Jr, Gagel RF. 2006. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21:354-365.
57. Tsuchida T, Sato K, Miyakoshi N, Abe T, Kudo T, Tamura Y, Kasukawa Y, Suzuki K. 2000. Histomorphometric evaluation of the recovering effect of human parathyroid hormone (1-34) on bone structure and turnover in streptozotocin-induced diabetic rats. Calcif Tissue Int 66:229-233.
58. Turner RT, Evans GL, Cavolina JM, Halloran B, Morey-Holton E. 1998. Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovariectomized rats. Endocrinology 139:4086-4091.
59. Turner RT, Evans GL, Lotinun S, Lapke PD, Iwaniec UT, Morey-Holton E. 2007. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 22:64-71.
60. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB. 2002. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321.
61. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. 2004. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426-438.
62. Vengellur A, LaPres JJ. 2004. The role of hypoxia inducible factor 1alpha in cobalt chloride induced cell death in mouse embryonic fibroblasts. Toxicol Sci 82:638-646.
63. Wiren KM, Zhang XW, Toombs AR, Kasparcova V, Gentile MA, Harada S, Jepsen KJ. 2004. Targeted overexpression of androgen receptor in osteoblasts: Unexpected complex bone phenotype in growing animals. Endocrinology 145:3507-3522.
64. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF. 2002. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res 17:2068-2079.